Scottish cost regulators are allowing routine use of a combination of Bristol-Myers Squibb's Opdivo and Yervoy for first-line treatment of patients with advanced melanoma on the National Health Service.
Three new medicines have been cleared for use by NHS Scotland by cost regulator the Scottish Medicines Consortium (SMC), bringing patients new options for breast cancer, fungal infection and warts